Vanguard Fiduciary Trust
MTNB icon

Vanguard Fiduciary Trust’s Matinas BioPharma MTNB Stock Holding History

Vanguard Fiduciary Trust’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6K Sell
1,154
-64
-5% -$618 ﹤0.01% 4037
2026
Q1 		$9.14K Buy
+1,218
New +$11.4K ﹤0.01% 4009

Other funds holding MTNB

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HIW
Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Vanguard Fiduciary Trust's MTNB Position: Q2 2026 in Review

Vanguard Fiduciary Trust reduced its Matinas BioPharma (MTNB) stake by 5.3% in Q2 2026, selling an estimated $618 and leaving 1,154 shares worth $10.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4037.

Vanguard Fiduciary Trust first reported a position in MTNB in Q1 2026 and has held it in 2 quarters since. 23 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.

  • Vanguard Fiduciary Trust held 1,154 shares of Matinas BioPharma worth $10.6K as of Q2 2026.
  • Vanguard Fiduciary Trust sold 64 Matinas BioPharma shares in Q2 2026, an estimated $618.
  • Matinas BioPharma made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #4037 holding.
  • Vanguard Fiduciary Trust first reported a position in Matinas BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 23 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.